Equities research analysts predict that Alpine Immune Sciences, Inc. (NASDAQ:ALPN – Get Rating) will announce earnings of ($0.39) per share for the current fiscal quarter, according to Zacks. Three analysts have issued estimates for Alpine Immune Sciences’ earnings, with the highest EPS estimate coming in at ($0.23) and the lowest estimate coming in at ($0.58). Alpine Immune Sciences posted earnings per share of ($0.46) during the same quarter last year, which would indicate a positive year over year growth rate of 15.2%. The business is expected to report its next quarterly earnings report on Monday, January 1st.
According to Zacks, analysts expect that Alpine Immune Sciences will report full year earnings of ($0.82) per share for the current fiscal year, with EPS estimates ranging from ($1.50) to $0.41. For the next financial year, analysts expect that the company will report earnings of ($1.63) per share, with EPS estimates ranging from ($1.94) to ($0.98). Zacks Investment Research’s EPS calculations are an average based on a survey of research firms that that provide coverage for Alpine Immune Sciences.
Alpine Immune Sciences (NASDAQ:ALPN – Get Rating) last announced its quarterly earnings results on Thursday, May 12th. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.06). Alpine Immune Sciences had a negative net margin of 139.41% and a negative return on equity of 46.87%.
Alpine Immune Sciences stock traded up $0.04 during mid-day trading on Tuesday, reaching $8.34. 138,779 shares of the stock traded hands, compared to its average volume of 113,061. The stock has a market capitalization of $252.94 million, a PE ratio of -4.69 and a beta of 1.74. The company has a debt-to-equity ratio of 0.02, a current ratio of 2.58 and a quick ratio of 2.58. Alpine Immune Sciences has a 12-month low of $6.00 and a 12-month high of $14.40. The business’s 50-day moving average is $8.61 and its 200-day moving average is $9.77.
Several large investors have recently added to or reduced their stakes in the stock. Barclays PLC boosted its stake in Alpine Immune Sciences by 223.1% during the third quarter. Barclays PLC now owns 4,747 shares of the biotechnology company’s stock valued at $51,000 after buying an additional 3,278 shares during the last quarter. Geode Capital Management LLC boosted its stake in Alpine Immune Sciences by 1.3% during the third quarter. Geode Capital Management LLC now owns 194,021 shares of the biotechnology company’s stock valued at $2,070,000 after buying an additional 2,483 shares during the last quarter. BlackRock Inc. boosted its stake in Alpine Immune Sciences by 0.7% during the third quarter. BlackRock Inc. now owns 547,782 shares of the biotechnology company’s stock valued at $5,844,000 after buying an additional 3,627 shares during the last quarter. Two Sigma Investments LP boosted its stake in Alpine Immune Sciences by 131.9% during the third quarter. Two Sigma Investments LP now owns 39,218 shares of the biotechnology company’s stock valued at $418,000 after buying an additional 22,304 shares during the last quarter. Finally, Frazier Management LLC boosted its stake in Alpine Immune Sciences by 0.7% during the fourth quarter. Frazier Management LLC now owns 1,784,913 shares of the biotechnology company’s stock valued at $24,721,000 after buying an additional 13,069 shares during the last quarter. Hedge funds and other institutional investors own 77.00% of the company’s stock.
Alpine Immune Sciences Company Profile (Get Rating)
Alpine Immune Sciences, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B cell cytokine antagonist for the treatment of B cell-mediated inflammatory and autoimmune diseases.
- Get a free copy of the StockNews.com research report on Alpine Immune Sciences (ALPN)
- Zoom Video Communications Is Primed To Launch Higher
- Veeva Systems: Increasing NDR and Other Wins
- Institutions Buy The Dip In Petco Health and Wellness Company
- Fundamental Strength Makes Williams-Sonoma One for Your Recovery Watchlist
- Autozone Edges Past Advanced Auto Parts In Q1 2022
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Alpine Immune Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpine Immune Sciences and related companies with MarketBeat.com's FREE daily email newsletter.